SAINT LAURENT, QUEBEC--(Marketwire - May 29, 2008) - IntelGenx Corp. (TSX VENTURE: IGX)(OTCBB: IGXT)(“IntelGenx” or the “Company”) today announced that the pilot clinical trial of the antidepressant CPI-300 shows strong positive results. The preliminary results of the fasted and fed studies show that CPI-300 is equivalent to the reference product. The product uses IntelGenx’s proprietary Versatab oral delivery technology and will address the largest market within the company’s current pipeline; the lucrative $15 billion antidepressant market. IntelGenx is on track with its development timeline and project commercialization by the second half of 2009.
